Aclaris Phase 2 ADMIRATION Trial Of Anti-TSLP Antibody Bosakitug In Atopic Dermatitis Misses Primary Endpoint Of EASI Percent Change At Week 24, Secondary Endpoints Also Not Met
Benzinga Newsdesk 2 days ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -- Aclaris Remains Focused on Prioritizing the Development of its
- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 -
- Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 -
